1. Home
  2. VSTS vs BEAM Comparison

VSTS vs BEAM Comparison

Compare VSTS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$6.66

Market Cap

996.9M

Sector

N/A

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.03

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTS
BEAM
Founded
1936
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
996.9M
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VSTS
BEAM
Price
$6.66
$27.03
Analyst Decision
Sell
Strong Buy
Analyst Count
4
12
Target Price
$5.95
$48.09
AVG Volume (30 Days)
3.1M
1.5M
Earning Date
01-30-2026
02-24-2026
Dividend Yield
0.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,734,839,000.00
$55,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.74
$26.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$13.53
52 Week High
$16.68
$35.25

Technical Indicators

Market Signals
Indicator
VSTS
BEAM
Relative Strength Index (RSI) 50.90 53.35
Support Level $6.43 $26.71
Resistance Level $6.87 $28.00
Average True Range (ATR) 0.42 1.23
MACD -0.10 -0.08
Stochastic Oscillator 24.22 47.95

Price Performance

Historical Comparison
VSTS
BEAM

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: